Diagnosis of Non-small Cell Lung Cancer for Early Stage Asymptomatic Patients

Goebel, Cherylle; Louden, Christopher; McKenna, Robert J.; Onugha, Osita I.; Wachtel, Andrew; Long, Thomas J.

doi:10.21873/cgp.20128

Cited by 76 publications

(54 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This information is proprietary and a patent application was filed. Patterns of up and down regulation of biomarkers were similar to our previous study [11]. The median concentration in LC patients compared to healthy non-smokers, asthma sufferers, and smokers was more than 200% higher in SAA (771%), MMP-9 (743%), IL-8 (535%), CXCL9/MIG (482%), TNFRI (406%), Gro (331%), MPO (300%), Rantes (274%), Resistin (271%), TNFRII (266), and MIF (219%).…”

Section: Resultssupporting

confidence: 88%

“…This study is a continuation of our previous research that used 33 biomarkers [11]. Here we reduced the number of biomarkers to 21, ensured successful transfer of reagents, and retrained our algorithm.…”

Section: Methodsmentioning

confidence: 93%

“…In narrowing our list, the biological justification for the selection of biomarkers was critical in avoiding numerical quirks that may mask the true driver of a physiological process [11]. To elaborate, the statistical model in the previous study was a Random Forest (RF) model.…”

Section: Discussionmentioning

confidence: 99%

“…There is a growing trend to use genetic and protein biomarkers for disease diagnosis, prognosis, and the evaluation of treatment efficacy (e.g., Grail, Guardant, Myriad Genetics) [11,12]. Biomarkers are defined as 'any substance, structure, or process that can be measured in the body or its products and influence or predict outcome or disease' [13].…”

Section: Evaluating Biomarkers To Detect Lcmentioning

confidence: 99%

“…Sample processing was performed by Eve Technologies Corporation (Calgary, Alberta, Canada). This assay reagent and format was validated against the 33-biomarker reagent used in the previous study [11] to ensure that all biomarkers performed similarly and maintained its congruity with the algorithm.…”

Section: Multiplexed Immunoassay Proceduresmentioning

confidence: 99%

See 4 more Smart Citations

Blood test shows high accuracy in detecting stage I non-small cell lung cancer

Goebel¹,

Louden²,

McKenna³

et al. 2020

BMC Cancer

Self Cite

View full text Add to dashboard Cite

Background: In a previous study (Goebel et. al, Cancer Genomics Proteomics 16:229-244, 2019), we identified 33 biomarkers for an early stage (I-II) Non-Small Cell Lung Cancer (NSCLC) test with 90% accuracy, 80.3% sensitivity, and 95.4% specificity. For the current study, we used a narrowed ensemble of 21 biomarkers while retaining similar accuracy in detecting early stage lung cancer. Methods: A multiplex platform, 486 human plasma samples, and 21 biomarkers were used to develop and validate our algorithm which detects early stage NSCLC. The training set consisted of 258 human plasma with 79 Stage I-II NSCLC samples. The 21 biomarkers with the statistical model (Lung Cancer Detector Test 1, LCDT1) was then validated using 228 novel samples which included 55 Stage I NSCLC. Results: The LCDT1 exhibited 95.6% accuracy, 89.1% sensitivity, and 97.7% specificity in detecting Stage I NSCLC on the blind set. When only NSCLC cancers were analyzed, the specificity increased to 99.1%.Conclusions: Compared to current approved clinical methods for diagnosing NSCLC, the LCDT1 greatly improves accuracy while being non-invasive; a simple, cost-effective, early diagnostic blood test should result in expanding access and increase survival rate.

show abstract

Section: Resultssupporting

confidence: 88%

Section: Methodsmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Evaluating Biomarkers To Detect Lcmentioning

confidence: 99%

Section: Multiplexed Immunoassay Proceduresmentioning

confidence: 99%

See 3 more Smart Citations

Blood test shows high accuracy in detecting stage I non-small cell lung cancer

Goebel¹,

Louden²,

McKenna³

et al. 2020

BMC Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Pelargonidin inhibits cell growth and promotes oxidative stress‐mediated apoptosis in lung cancer A549 cells

Yue,

Li,

Luo

et al. 2024

Biotech and App Biochem

View full text Add to dashboard Cite

Lung cancer has the worst prognosis with an average 5‐year survival rate of only 10%–20%. Lung cancer has the highest prevalence rate and a second most common cause of cancer‐associated mortalities worldwide. The present study was planned to explore the anticancer effects of pelargonidin against the lung cancer A549 cells via analyzing oxidative stress‐mediated apoptosis. The viability of both control and pelargonidin‐treated A549 cells was analyzed using the MTT cytotoxicity assay at different time periods. The levels of endogenous ROS generation, mitochondrial membrane potential (Δψm), and apoptosis were assessed using corresponding fluorescent staining assays. The levels of oxidative stress biomarkers, including TBARS, SOD, CAT, and GSH, in the cell lysates of control and pelargonidin‐treated A549 cells were examined using the assay kits. The pelargonidin treatment substantially suppressed the A549 cell growth. Further, pelargonidin promoted the ROS production and depleted the Δψm levels in the A549 cells. The fluorescent staining assays witnessed the occurrence of increased apoptosis in the pelargonidin‐treated A549 cells. The pelargonidin also boosted the TBARS and reduced the antioxidant levels thereby promoted the oxidative stress‐regulated apoptosis in the A549 cells. In summary, the findings’ results of the current study demonstrated an anticancer activity of pelargonidin on A549 cells. The pelargonidin treatment substantially decreased the growth and encouraged the oxidative stress‐regulated apoptosis in A549 cells. Therefore, it was evident that the pelargonidin could be employed as an effective anticancer candidate to treat the lung cancer.

show abstract

Multiplexed fluorescence in situ hybridization–based detection of circulating tumor cells: A novel liquid‐based technology to facilitate accurate and early identification of non–small cell lung cancer patients

Zhu

Lowe

2020

Cancer Cytopathology

View full text Add to dashboard Cite

Lung cancer has the highest mortality and morbidity rate among all malignancies. Because almost all patients are asymptomatic in the early stages of cancer development, the majority of patients are diagnosed with advanced disease. 1 Unfortunately, most of these patients cannot be cured with current therapies. The early detection of lung cancer can provide a window of opportunity to improve care and provide effective treatment to patients at a time when they may be cured. In the United States, the only recommended screening test for lung cancer is low-dose computed tomography (LDCT). 2 LDCT has shown a mild but significant reduction in lung cancer-related deaths and all-cause mortality 3 ; however, it yields a high false-positive discovery rate that exposes patients with nonmalignant lung nodules to unnecessary biopsy-related risks. Therefore, a minimally invasive, easily repeatable, accurate method of lung cancer detection is needed to identify the cohort of at-risk patients who develop disease. Such a method may also be effective in monitoring disease progression or response to therapy.Circulating tumor cell (CTC) technology has emerged and expanded exponentially in the field of liquid biopsy in recent decades. CTCs are rare tumor cells found in the peripheral blood of patients with cancer and can be reliably detected by multiple different CTC platforms. CTCs have been shown to contain a similar genomic landscape to the primary tumors from which they have arisen, 4-7 thus providing valuable insight into the diagnosis and further characterization of primary and metastatic tumors. The critical challenge for these technologies is accurate identification and isolation of extremely rare CTCs from blood (ie, on the order of 10 −9 of all blood cells). A majority of CTC isolation/enrichment techniques employ immunomagnetic capture of epithelial cell adhesion molecule (EpCAM)-positive cells to identify CTCs 8 ; however, these relatively well-established techniques are limited by dependence on EpCAM antibody efficiency and heterogeneity in CTC EpCAM expression. Thus, researchers have also developed alternative enrichment methods based on biophysical properties of CTC, such as size-based filtration and density-based gradient centrifugation. 8 These CTC technologies yield liquid specimens containing tumor cells that can provide diagnostic, prognostic, and predictive information for oncologic patients, and can serve as a valuable extension of diagnostic cytopathology.In this issue of Cancer Cytopathology, Katz et al 9 demonstrate successful detection of cytogenetic changes in peripheral blood mononuclear cells from patients with early stage non-small cell lung carcinoma (NSCLC). The authors modified their previous 2-color FISH detection assay 10 and developed a 4-color FISH-based assay to identify cytogenetic changes and quantify circulating tumor cells (CTCs) from the peripheral blood of patients who are at risk for developing NSCLC. The technique they developed shares similarities with the

show abstract

Diagnosis of Non-small Cell Lung Cancer for Early Stage Asymptomatic Patients

Cited by 76 publications

References 21 publications

Blood test shows high accuracy in detecting stage I non-small cell lung cancer

Blood test shows high accuracy in detecting stage I non-small cell lung cancer

Pelargonidin inhibits cell growth and promotes oxidative stress‐mediated apoptosis in lung cancer A549 cells

Multiplexed fluorescence in situ hybridization–based detection of circulating tumor cells: A novel liquid‐based technology to facilitate accurate and early identification of non–small cell lung cancer patients

Contact Info

Product

Resources

About